LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Ventyx Biosciences Inc

Cerrado

2.46 2.5

Resumen

Variación precio

24h

Actual

Mínimo

2.36

Máximo

2.5

Métricas clave

By Trading Economics

Ingresos

1.9M

-27M

BPA

-0.39

Empleados

81

EBITDA

2.4M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+373.03% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

58M

161M

Apertura anterior

-0.04

Cierre anterior

2.46

Ventyx Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 sept 2024, 12:43 UTC

Principales Movimientos del Mercado

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Comparación entre iguales

Cambio de precio

Ventyx Biosciences Inc previsión

Precio Objetivo

By TipRanks

373.03% repunte

Estimación a 12 Meses

Media 11.4 USD  373.03%

Máximo 21 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ventyx Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

5

Comprar

3

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.